Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: Similar clinical results and minor biochemical differences

European Journal of Cardio-thoracic Surgery

Volumn 16, Issue 2, 1999, Pages 211-217

  Wimmer Greinecker, Gerhard ^a   Matheis, Georg ^a   Martens, Sven ^a   Oremek, Gerhard ^b   Abdel Rahman, Ulf ^a   Moritz, Anton ^a  

^a Herz Gefachirurgie J ^*  (Germany)

^b Dept Int Med (Zentrallabor Z   (Germany)

Author keywords

Cardiopulmonary bypass; Coronary artery bypass grafting; Heparin coating; Inflammatory whole body response; Synthetic protein treatment

Indexed keywords

HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; NEURON SPECIFIC ENOLASE; PROTEIN; PROTEIN S 100;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BRAIN INJURY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OXYGENATOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURFACE PROPERTY; THROMBOCYTE COUNT;

AGED; ANTICOAGULANTS; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; CREATINE KINASE; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; OXYGENATORS, MEMBRANE; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROTEINS; S100 PROTEINS; TROPONIN T;

EID: 0032764735     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(99)00143-8     Document Type: Article

References (28)

1. Nolan S.P., Zacour R., Damman J.F. Reflections on the evolution of cardiopulmonary bypass. Ann Thorac Surg. 64:(5):1997;1540-1543.
2. Stammers A.H. Historical aspects of cardiopulmonary bypass: from antiquity to acceptance. J Cardiothorac Vasc Anesth. 11:(3):1997;266-274.
3. Mack M.J. Perspectives on minimally invasive coronary artery surgery. Current assessment and future directions. Int J Cardiol. 62(Suppl.1):1997;S73-S79.
4. Utley J.R. The history of the concept of inflammatory responses to cardiopulmonary bypass. Perfusion. 11:(3):1996;190-195.
5. Videm V., Svennevig J.L., Fosse E., Semb G., Osterud A., Mollnes T.E. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg. 103:(4):1992;806-813.
6. Daniel S. Review on the multifactorial aspects of bioincompatibility in CPB. Perfusion. 11:(3):1996;246-255.
7. Gravlee G.P. Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesth. 8:(2):1994;213-222.
8. Gu Y.J., Boonstra P.W., Rijnsburger A.A., Haan J., van Oeveren W. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility. Ann Thorac Surg. 65:(5):1998;1342-1347.
9. von Segesser L.K., Lachat M., Leskosek B., Gallino A., Weiss B.M., García E., Hanseler E., von Felteu A., Turina M. Cardiopulmonary bypass with low systemic heparinization. An experimental study. Perfusion. 5:1990;267-276.
10. von Segesser L.K., Turina M. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators. J Thorac Cardiovasc Surg. 98:1989;386-396.
11. Gu Y.J., van Oeveren W., van der Kamp K.W.H.J., Akkerman C., Chiang B.Y., van Vliet M.H., Wildevuur C.R. Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion. 6:1991;221-225.
12. Gu Y.J., van Oeveren W., Akkerman C., Boonstra P.W., Huyzen R.J., Wildevuur C.R. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:(4):1993;917-922.
13. Wan S., Marchant A., DeSmet J.M., Antoine M., Zhang H., Vachiery J.L., Goldman M., Vincent J.L., LeClerc J.L. Human cytokine responses to cardiac transplantation and coronary artery bypass grafting. J Thorac Cardiovasc Surg. 111:(2):1995;469-477.
14. Gott V.L., Whiffen J.D., Dutton R.C. Heparin bonding on colloidal graphite surfaces. Science. 142:1963;1297-1298.
15. Borowiec J., Bagge L., Saldeen T., Thelin S. Biocompatibility reflected by hemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Thorac Cardiovasc Surg. 45:(4):1997;163-167.
16. Baier R.E., Dutton R.C. Initial events in interactions of blood with foreign surface. J Biomed Mater Res. 3:1969;191-206.
17. McCutcheon J.G. Clinical application of heparin treated extracorporeal circuits and the mechanism of action of immobilized surface heparin surface treatments. Proceedings of the American Academy of Cardiovascular Perfusion. AACP. 12:1991;54-56.
18. Wahba A., Philipp A., Behr R., Birnbaum D.E. Heparin-coated equipment reduces the risk of oxygenator failure. Ann Thorac Surg. 65:1998;1310-1312.
19. Bagge L., Thelin S., Hultman J., Nilsson L., Thorelius J., Hillstrom P.A. Heparin-coated CPB sets increase biocompatibility and reduce endothelial cell damage in pigs. J Cardiothorac Anesth. 3(5,Suppl.1):1989;84.
20. Mollnes T.E., Videm Y., Gotze O., Harboe M., Oppermann M. Formation of C5b during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg. 52:(1):1991;92-97.
21. Gravlee G.P., Phipps J., Mills S.A. Hematologic evaluation of a heparin-coated circuit for cardiopulmonary bypass. Anesthesiology. 77:1992;A99.
22. Matheis G., Wimmer-Greinecker G., Winkelmann B.R., Baum R.P., Oremek G., Skupin M., Moritz A. Reduced neuronal injury, limited neutrophil activation and complement activation with heparin coated extracorporeal circuit. Circulation. 94(8 Suppl.I):1996;115.
23. Palatianos G.M., Dewanjee M.K., Kapadvanjwala M. Cardiopulmonary bypass with a surface-heparinized extracorporeal perfusion system. ASAIO Trans. 36:1990;M476-M479.
24. Steinberg J.B., Kapelanski D.P., Olson J.D., Weiler J.M. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1008-1016.
25. Nathan N., Denizot Y., Cornu E., Jauberteau M.O., Chauvreau C., Feiss P. Cytokine and lipid mediator blood concentrations after coronary artery surgery. Anesthesia Analgesia. 85:1997;1240-1246.
26. Westaby S., Johnsson P., Parry A.J., Blomquist S., Solem J.O., Alling C., Pillai R., Taggart D.P., Grebenik C., Stahl E. Serum S100 protein: a potential marker for cerebral events during cardiopulmonary bypass. Ann Thorac Surg. 61:1996;88-92.
27. Persson L., Hardemark H.G., Gustafsson J., Rundstrom G., Mendel-Hartvig I., Esscher T., Pahlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 18:(5):1987;911-918.
28. Johnsson P., Lundqvist C., Lindgren A., Ferencz I., Alling C., Stahl E. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. J Cardiothorac Vasc Anesthesia. 9:1995;694-699.